Print
|
Close
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Active:
Yes
Cancer Type:
Cancer-Related Syndrome
Leukemia
Myelodysplastic Syndromes (MDS)
NCT ID:
NCT04279847
Trial Phases:
Phase I
Protocol IDs:
INCB 57643-103 (primary)
NCI-2020-07097
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Incyte Corporation
NCI Full Details:
http://clinicaltrials.gov/show/NCT04279847
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy
of INCB057643 as monotherapy or combination with ruxolitinib for participants with
myelofibrosis (MF) and other myeloid neoplasms.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.